Company & Sponsor Intelligence
Astellas Pharma Inc
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries2
Therapeutic footprint
depressionout_of_scopestroke
Indexed studies
NCT00044057A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
stroke · United StatesPHASE2
stroke · United StatesPHASE2
NCT00413218Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT01924520Oral Multiple-dose Study in Patients With Major Depressive Disorder
depression · JapanPHASE1
depression · JapanPHASE1
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →